Oxamic acid

SKU: orb2802383

Description

Oxamic acid is a small molecule inhibitor of lactate dehydrogenase A (LDHA) with demonstrated antitumor properties. It has been shown in research studies to induce apoptosis, suppress EGFR expression, and inhibit cancer stemness and epithelial-mesenchymal transition (EMT) in various in vitro cancer models.

Research Area

Cardiovascular Research, Metabolism Research, Signal Transduction

Key Properties

• CAS Number: 471-47-6
• MW: 89.05
• Formula: C₂H₃NO₃
• SMILES: O=C(O)C(=O)N
• Target: Dehydrogenase,EGFR
• Solubility: H2O:40 mg/mL (449.19 mM)

Bioactivity

• In Vivo:
  Compared to using Oxamic acid alone or radiation therapy alone, the combination of Oxamic acid (750 mg/kg, intraperitoneal injection, once daily for 3 weeks) with radiation therapy significantly enhanced tumor suppression effects in female Balb/c nude mice inoculated with CNE-1 cells .
• In Vitro:
  After 24-72 hours of treatment with 10 μM Oxamic acid, cell proliferation in nasopharyngeal carcinoma cells was inhibited in a dose- and time-dependent manner . Exposure to 0-100 mM oxamate for 24 hours induced G2/M phase cell cycle arrest in CNE-1 and CNE-2 cells . Treatment with 0-100 mM oxamate for 48 hours activated caspase-3 and the mitochondrial pathway, leading to apoptosis in nasopharyngeal carcinoma cells . Following 24-hour exposure to 0-100 mM oxamate, intracellular reactive oxygen species levels were elevated in nasopharyngeal carcinoma cells .

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Oxamidic acid

Compound Identifiers

PubChem CID

974